title: Pure red-cell aplasia associated with pegylated interferon-alpha-2b plus ribavirin.
authors.forename: Yuji
authors.initials: Y
authors.lastname: Miura
authors.forename: Masahiro
authors.initials: M
authors.lastname: Kami
authors.forename: Ron
authors.initials: R
authors.lastname: Yotsuya
authors.forename: Nobuo
authors.initials: N
authors.lastname: Toda
authors.forename: Tsunehiko
authors.initials: T
authors.lastname: Komatsu
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects*; D019698:Hepatitis C, Chronic / Q000097:blood / Q000188:drug therapy; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D012010:Red-Cell Aplasia, Pure / Q000139:chemically induced*; D012254:Ribavirin / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b